McKESSON REPORTS FISCAL 2027 SECOND QUARTER RESULTS AND RAISES FULL YEAR ADJUSTED EPS GUIDANCE IRVING, Texas, November 4, 2026 - McKesson Corporation (NYSE:MCK) today announced results for the second quarter ended September 30, 2026. Second Quarter Highlights: • Consolidated revenues of $111.0 billion increased 8%. • Earnings per diluted share of $10.44 increased $1.52. • Adjusted Earnings per Diluted Share of $11.68 increased 18%. • Generated $3.1 billion of cash flow from operations and $2.9 billion of Free Cash Flow. Fiscal 2027 Full Year Outlook: • Raised Adjusted Earnings per Diluted Share guidance range to $45.60 to $46.40, from the previous range of $44.20 to $45.00. • Fiscal 2027 Adjusted Earnings per Diluted Share guidance range indicates 17% to 19% growth compared to the prior year. • The Company does not forecast GAAP earnings per diluted share1. “McKesson delivered another quarter of strong results, reflecting operational strength in our core business segments and disciplined execution across the enterprise,” said Brian Tyler, chair and chief executive officer. “We continue to invest strategically to advance healthcare outcomes and create long-term value. We further strengthened our portfolio through transactions that will expand our capabilities and deepen our presence in key growth areas, while maintaining our commitment to financial discipline. We are confident in our ability to leverage differentiated solutions and create value for customers, partners, patients, and shareholders. As we close out a strong first half of our fiscal year, I want to thank Team McKesson for their unwavering commitment to excellence and for the impact they make across healthcare every day.” Fiscal 2027 Second Quarter Result Summary Second Quarter ($ in millions, except per share amounts)
Revenues Net income attributable to McKesson Corporation Adjusted Earnings2 Earnings per diluted common share attributable to McKesson Corporation Adjusted Earnings per Diluted Share2
Year-to-Date
FY27 $110,957
FY26 $103,150
% Change 8
FY27 $ 216,337
FY26 $ 200,977
% Change 8
1,218 1,363
1,110 1,227
10 11
1,832 2,546
1,894 2,264
(3) 12
10.44 11.68
8.92 9.86
17 18
15.53 21.59
15.16 18.12
2 19
Second quarter revenues were $111.0 billion, an increase of 8% from a year ago, driven by growth in the North American Pharmaceutical and Oncology & Multispecialty segments due to increased prescription volumes and distribution of specialty products, partially offset by lower contributions from branded pharmaceuticals. Second quarter earnings per diluted share was $10.44 compared to $8.92 a year ago, an increase of $1.52. 1
See below under "Fiscal 2027 Outlook" for full explanation Adjusted results in this earnings release are non-GAAP financial measures; refer to the accompanying definitions and reconciliation schedules
2
Second quarter Adjusted Earnings per Diluted Share was $11.68 compared to $9.86 a year ago, an increase of 18%, driven by strong operational growth across the North American Pharmaceutical, Oncology & Multispecialty, and Prescription Technology Solutions segments, and a lower share count. During the three months ended September 30, 2026, McKesson generated cash from operations of $3.1 billion, and invested $123 million in capital expenditures, resulting in Free Cash Flow of $2.9 billion. During the first six months of the fiscal year, McKesson generated cash from operations of $2.9 billion, and invested $275 million in capital expenditures, resulting in Free Cash Flow of $2.6 billion. For the first six months of the fiscal year, McKesson returned $3.6 billion of cash to shareholders, which included $3.4 billion of common stock repurchases and $198 million of dividend payments. Business Highlights • McKesson signed an agreement to extend its pharmaceutical distribution partnership with CVS Health through June 2032. • On October 5, 2026, McKesson signed a definitive agreement to invest approximately $1.4 billion for a minority interest of approximately 49% in Option Care Health, Inc. This transaction aligns with McKesson’s strategy in supporting the delivery of complex specialty therapies and expanding patient access through community-based care. The transaction is subject to customary closing conditions, including approval by Option Care Health’s stockholders and the receipt of required regulatory approvals. • On November 2, 2026, McKesson completed the acquisition of Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization service. This acquisition represents a meaningful milestone in advancing its strategy in oncology, multispecialty, and biopharma services. • On November 2, 2026, PRISM Vision Group expanded its network with the addition of Spectrum Vision Partners, adding more than 150 providers and bringing its total provider network to more than 350. North American Pharmaceutical Segment • Revenues were $91.4 billion, an increase of 6%, driven by increased prescription transaction volumes, including higher volumes from specialty products to health systems and strategic accounts, partially offset by lower contributions from branded pharmaceuticals. • Segment Operating Profit was $1.1 billion. Adjusted Segment Operating Profit was $1.0 billion, an increase of 22%, driven by growth in the distribution of specialty products to health systems and strategic accounts. Oncology & Multispecialty Segment • Revenues were $15.0 billion, an increase of 24%, driven by growth in provider solutions and specialty distribution. • Segment Operating Profit was $352 million. Adjusted Segment Operating Profit was $427 million, an increase of 8%, driven by growth in provider solutions and specialty distribution. Prescription Technology Solutions Segment • Revenues were $1.5 billion, an increase of 10%, driven by increased prescription volumes in third-party logistics and access solutions, partially offset by lower contributions from hub dispensing services. • Segment Operating Profit was $275 million. Adjusted Segment Operating Profit was $307 million, an increase of 18%, driven by higher demand for access solutions.
Medical-Surgical Solutions Segment • Revenues were $3.1 billion, an increase of 5%, driven by growth across the extended and ambulatory care channels. • Segment Operating Profit was $164 million. Adjusted Segment Operating Profit was $225 million, a decrease of 10%, driven by lower contributions from the ambulatory care channel due to product mix, partially offset by growth in the extended care channel. Fiscal 2027 Outlook McKesson does not provide forward-looking guidance on a GAAP basis as the company is unable to provide a quantitative reconciliation of forward-looking Non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort. McKesson cannot reasonably forecast LIFO inventory-related adjustments, certain litigation loss and gain contingencies, transaction related expenses and adjustments, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate. These items are generally uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially. McKesson is raising its fiscal 2027 Adjusted Earnings per Diluted Share guidance to $45.60 to $46.40 from the previous range of $44.20 to $45.00. “The raise in fiscal 2027 Adjusted Earnings per Diluted Share guidance is underpinned by the strength in our business and the confidence we have in our ability to execute consistently,” said Kenny Cheung, executive vice president and chief financial officer. “We are committed to building towards the future through disciplined capital deployment and strategic investments.” Additional modeling considerations will be provided in the earnings call presentation. Conference Call Details McKesson has scheduled a conference call for today, Wednesday, November 4, 2026, at 4:30 PM ET to discuss the company’s financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website at investor.mckesson.com. Upcoming Investor Events McKesson management will participate in the following investor events: • Jefferies Global Healthcare Conference, November 17, 2026 • Evercore Healthcare Conference, December 1, 2026 • J.P. Morgan Healthcare Conference, January 11-14, 2027 A complete listing of public events open to the investment community will be available on McKesson's Investor Relations website, including details, updates, and a link to each webcast. Non-GAAP Financial Measures GAAP refers to the U.S. generally accepted accounting principles. This press release includes GAAP financial measures as well as Non-GAAP financial measures, including Adjusted Gross Profit, Adjusted Operating Expenses, Adjusted Other Income, Adjusted Interest Expense, Adjusted Income Tax Expense, Adjusted Earnings, Adjusted Earnings per Diluted Share, Adjusted Segment Operating Profit, Adjusted Segment Operating Profit Margin, Adjusted Corporate Expenses, Adjusted Operating Profit, and Free Cash Flow which are financial measures not calculated in accordance with GAAP. Refer to the “Supplemental NonGAAP Financial Information” section of the accompanying financial statement tables for the definitions and usefulness of the company’s Non-GAAP financial measures and the attached schedules for reconciliations of the differences between the Non-GAAP financial measures and their most directly comparable GAAP financial measures.
Cautionary Statements This earnings release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by their use of terminology such as “believes,” “expects,” “anticipates,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “projects,” “plans,” “estimates,” “targets,” or the negative of these words or other comparable terminology. Any discussion of our intent to separate our Medical-Surgical Solutions segment into an independent company, other anticipated or completed transactions, including the anticipated closings thereof, or synergies expected therefrom, litigation outcomes, financial outlook, guidance, trends, strategy, plans, assumptions, expectations, commitments, and intentions may also include forward-looking statements. Forward-looking statements are not representations of historical or current facts or circumstances and they involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Readers should not place undue reliance on forward-looking statements, such as financial performance forecasts, which speak only as of the date they are first made. Except to the extent required by federal securities laws, we undertake no obligation to publicly release the result of any revisions to any forward-looking statements to reflect events or circumstances after the date the statements are made, or to reflect the occurrence of unanticipated events. Although it is not possible to predict or identify all such risks and uncertainties, we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases. These risk factors include, but are not limited to: our planned separation of Medical-Surgical Solutions and the closing of our investment in Option Care Health, Inc., each of which is subject to conditions, may not be completed on the currently contemplated terms or timeline, or at all, and, if completed, may not achieve the intended financial and strategic benefits; we experience costly and disruptive legal disputes and settlements, including regarding our role in distributing controlled substances such as opioids; we experience losses not covered by insurance or indemnification; we are subject to frequently changing, extensive, complex, and challenging healthcare and other laws and policies; we from time to time record significant charges from impairment to goodwill, intangibles, and other long-lived assets; we experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches; we experience significant problems with information systems or networks; the adoption and use of artificial intelligence in our business operations exposes us to risks and uncertainties; we may be unsuccessful in achieving our strategic growth objectives; we may be unsuccessful in our efforts to implement initiatives to reduce or optimize our costs; we might be unable to successfully complete or integrate acquisitions or other strategic transactions, especially in the timeframes noted; we may not receive anticipated benefits from acquisitions or other strategic transactions; we might be adversely impacted by delays or other difficulties with divestitures; we are impacted by customer purchase reductions, contract non-renewals, payment defaults, and bankruptcies; our contracts with government entities involve future funding, payment, and compliance risks; we might be harmed by changes in our relationships or contracts with suppliers; our use of third-party data is subject to risks and limitations that could impede the growth of our data services business; we might be unable to successfully recruit and retain qualified employees; we might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models; we might be adversely impacted by competition and industry consolidation; we are adversely impacted by changes or disruptions in product supply and have difficulties in sourcing or selling products due to a variety of causes; we are adversely impacted as a result of our distribution of generic pharmaceuticals; we are adversely impacted by changes in the economic environments in which we operate; changes affecting capital and credit markets might impede access to credit, increase borrowing costs, and disrupt banking services for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers; we might be adversely impacted by changes in tax legislation or challenges to our tax positions; and we might be adversely impacted by conditions and events outside of our control, such as widespread public health issues, natural disasters, and geopolitical factors.
About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights. We routinely use our website, investor.mckesson.com, to post information that may be material to investors, such as business developments, earnings, and financial performance, as well as presentation materials and details for upcoming and past events.